氘丁苯那嗪治疗奥氮平所致高龄老年人迟发性运动障碍1例
Deutetrabenazine for the Treatment of Tardive Dyskinesia Induced by Olanzapine in an Elderly Patient: A Case Report
DOI: 10.12677/ijpn.2024.134010, PDF,   
作者: 陶万清, 张瑞萍：云南省滇南中心医院老年医学科，云南 个旧
关键词: 迟发性运动障碍；氘丁苯那嗪；老年人；抗精神病药物；Tardive Dyskinesia； Deutetrabenazine； The Elderly； Antipsychotic Drugs
摘要: 关于氘丁苯那嗪治疗奥氮平引起的高龄老年人迟发性运动障碍的案例报道较为少见。本文特别对这一病例的诊断过程和治疗效果进行了详细阐述，旨在增进临床医生对这一病症的理解，并为未来的临床实践提供参考和借鉴经验。
Abstract: There are limited case reports on the use of deuterobutyl benazine for the treatment of olanzapine-induced tardive dyskinesia in elderly patients. This paper provides a detailed account of the diagnosis process and treatment outcome of such a case, with the goal of improving clinicians’ understanding of this condition and offering insights and experience for future clinical practice.
文章引用：陶万清, 张瑞萍. 氘丁苯那嗪治疗奥氮平所致高龄老年人迟发性运动障碍1例[J]. 国际神经精神科学杂志, 2024, 13(4): 81-84. https://doi.org/10.12677/ijpn.2024.134010

参考文献

[1] Woerner, M.G., Alvir, J.M.J., Saltz, B.L., Lieberman, J.A. and Kane, J.M. (1998) Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors. American Journal of Psychiatry, 155, 1521-1528. [Google Scholar] [CrossRef] [PubMed]
[2] Waln, O. and Jankovic, J. (2013) An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor and Other Hyperkinetic Movements, 3. [Google Scholar] [CrossRef] 
[3] Caroff, S.N., Ungvari, G.S. and Cunningham Owens, D.G. (2018) Historical Perspectives on Tardive Dyskinesia. Journal of the Neurological Sciences, 389, 4-9. [Google Scholar] [CrossRef] [PubMed]
[4] Bashir, H. and Jankovic, J. (2018) Deutetrabenazine for the Treatment of Huntington’s Chorea. Expert Review of Neurotherapeutics, 18, 625-631. [Google Scholar] [CrossRef] [PubMed]
[5] Dorfman, B.J. and Jimenez-Shahed, J. (2020) Deutetrabenazine for Treatment of Involuntary Movements in Patients with Tardive Dyskinesia. Expert Review of Neurotherapeutics, 21, 9-20. [Google Scholar] [CrossRef] [PubMed]
[6] 尹航, 侯梦雨, 张美娟, 等. 基于FAERS数据库的丁苯那嗪与氘丁苯那嗪安全性对比研究[J]. 现代药物与临床, 2023, 38(3): 702-708.
[7] Anderson, K.E., Stamler, D., Davis, M.D., Factor, S.A., Hauser, R.A., Isojärvi, J., et al. (2017) Deutetrabenazine for Treatment of Involuntary Movements in Patients with Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Psychiatry, 4, 595-604. [Google Scholar] [CrossRef] [PubMed]
[8] Fernandez, H.H., Factor, S.A., Hauser, R.A., Jimenez-Shahed, J., Ondo, W.G., Jarskog, L.F., et al. (2017) Randomized Controlled Trial of Deutetrabenazine for Tardive Dyskinesia. Neurology, 88, 2003-2010. [Google Scholar] [CrossRef] [PubMed]
[9] Hauser, R.A., Barkay, H., Fernandez, H.H., Factor, S.A., Jimenez-Shahed, J., Gross, N., et al. (2022) Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated with Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. Frontiers in Neurology, 13, Article 773999. [Google Scholar] [CrossRef] [PubMed]
[10] Anderson, K.E., Stamler, D., Davis, M.D., Hauser, R.A., Jarskog, L.F., Jimenez-Shahed, J., et al. (2019) 34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. CNS Spectrums, 24, 193-193. [Google Scholar] [CrossRef]